Bolt Biotherapeutics SEC filings document the company’s public-company governance, financial-results reporting, and clinical-stage oncology disclosures. Recent Form 8-K reports furnish quarterly and annual results and business updates for BDC-4182 and the Boltbody™ ISAC platform, while proxy materials describe director elections, auditor ratification, and stockholder meeting mechanics.
The filing record also includes emerging growth company status, restructuring disclosures under exit or disposal activity rules, estimated severance and benefit costs, and updates on pipeline and capital-preservation measures. These filings frame Bolt’s governance procedures, operating expense controls, reporting status, and development-stage business disclosures as a Nasdaq-listed biopharmaceutical issuer.
Bolt Biotherapeutics, Inc., a clinical-stage oncology company, reported a Q2 2026 net loss of $7.7 million and a six‑month net loss of $15.0 million, both narrower than in 2025 due to a major October 2025 restructuring that cut headcount by about 50% and lowered research and development and general and administrative expenses. Collaboration revenue fell sharply to $5,000 in Q2 and $31,000 for the first half, from $1.8 million and $3.0 million a year earlier, reflecting limited current collaboration activity with Toray and Genmab.
Cash, cash equivalents and marketable securities totaled $18.1 million as of June 30, 2026. Management states this may fund operations only into the first quarter of 2027 and concludes there is substantial doubt about the company’s ability to continue as a going concern without additional capital. An $0.8 million non‑cash impairment charge was recorded on right‑of‑use assets after a sublessee gave termination notice on part of the main facility. The company continues to advance its lead ISAC candidate BDC‑4182 in an ongoing Phase 1/2 trial in gastric and gastroesophageal junction cancer.
Bolt Biotherapeutics reported second quarter 2026 results while emphasizing progress in its lead oncology program. The Phase 1/2 trial of BDC-4182, a first-in-class immune-stimulating antibody conjugate targeting claudin 18.2, is ongoing in gastric and gastroesophageal cancers, with patients now being treated in Cohort 4 at the 4.0 mg/kg dose level. Initial clinical data are expected to be released with the company’s third quarter 2026 results.
Financially, collaboration revenue for the quarter was $5,000 versus $1.8 million a year earlier, reflecting a sharp decline in R&D collaboration activity. Operating discipline offset some of this impact: R&D expenses fell to $5.1 million from $7.5 million and G&A to $2.4 million from $3.5 million, aided by prior restructuring. Net loss for the quarter narrowed to $7.7 million from $8.6 million, and for the first half of 2026 to $15.0 million from $19.6 million. Cash, cash equivalents and marketable securities totaled $18.1 million as of June 30, 2026, which the company expects will fund operations into the first quarter of 2027, while the rest of its pipeline remains on hold pending further progress and partnering.
Bolt Biotherapeutics director Laura Berner received a grant of stock options for 5,000 shares of common stock. The options have an exercise price of $4.43 per share and expire on June 9, 2036.
The award vests on the earlier of June 9, 2027 or the day immediately before the next annual meeting of stockholders, as long as she remains in continuous service until that date. The options will vest in full if there is a change in control of Bolt Biotherapeutics before then. This is an acquisition of derivative securities by grant, not an open-market stock purchase or sale.
Bolt Biotherapeutics director Kathleen LaPorte received a stock option grant for 5,000 shares of common stock. The option has an exercise price of $4.43 per share and expires on June 9, 2036. It vests on the earlier of June 9, 2027 or the day immediately before the next annual stockholder meeting, assuming continuous service. The option will vest in full if there is a change in control of Bolt Biotherapeutics.
Bolt Biotherapeutics director Jakob Dupont received a stock option grant covering 5,000 shares of common stock. The option has an exercise price of $4.43 per share and expires on June 9, 2036. It vests on the earlier of June 9, 2027 or the day before the next annual stockholder meeting, with full vesting upon a change in control, assuming continuous service.
Bolt Biotherapeutics director Brian O’Callaghan received a grant of stock options covering 5,000 shares of common stock. The options have an exercise price of $4.43 per share and expire on June 9, 2036. Following this grant, he holds options on 5,000 shares.
The options will vest on the earlier of June 9, 2027 or the day immediately before the next annual stockholder meeting, as long as he remains in continuous service. They also vest in full if there is a change in control of Bolt Biotherapeutics.
Bolt Biotherapeutics director Nicole Onetto received a grant of stock options for 5,000 shares of common stock. The options have an exercise price of $4.43 per share and were awarded as a compensation-related grant, not an open-market purchase.
The filing shows she now holds stock options covering 5,000 shares directly after this transaction. These options vest on the earlier of June 9, 2027 or the day immediately before Bolt Biotherapeutics’ next annual stockholder meeting, subject to her continued service. The options will vest in full if there is a change in control of the company.
Bolt Biotherapeutics, Inc. reported the results of its 2026 annual stockholder meeting. Stockholders elected William P. Quinn and Jakob Dupont, M.D. as Class II directors to serve until the 2029 annual meeting or until a successor is chosen.
A total of 1,921,567 common shares were entitled to vote as of April 22, 2026, with 877,358 shares represented in person or by proxy. Stockholders also ratified PricewaterhouseCoopers LLP as the independent registered public accounting firm for the year ending December 31, 2026.
Bolt Biotherapeutics, Inc. reported a net loss of $7.2 million for the three months ended March 31, 2026, compared with $11.0 million a year earlier, as it continues developing its Boltbody immunotherapies for cancer.
Collaboration revenue fell to $26,000 from $1.2 million, reflecting limited current activity with partners Toray and Genmab. Research and development expenses declined to $4.8 million and general and administrative expenses to $2.8 million, largely due to a 2025 restructuring that halved the workforce.
Cash, cash equivalents and marketable securities totaled $23.9 million as of March 31, 2026. Management believes this may fund operations into early 2027, but the company states there is “substantial doubt” about its ability to continue as a going concern without additional capital, and it expects to seek funding through partnerships, equity or other means.
Bolt Biotherapeutics reported first quarter 2026 results and a business update. Collaboration revenue was $26,000 compared with $1.2 million a year earlier as work under R&D collaborations declined. Research and development expenses fell to $4.8 million from $9.5 million, and general and administrative expenses declined to $2.8 million from $3.8 million, reflecting restructuring and lower clinical and research costs. Loss from operations narrowed to $7.6 million, with net loss at $7.2 million.
The company ended March 31, 2026 with $23.9 million in cash, cash equivalents, and marketable securities, which it expects will fund operations into 2027. Bolt’s lead program, BDC‑4182, a first‑in‑class immune‑stimulating antibody conjugate targeting claudin 18.2, is in an ongoing Phase 1/2 trial in gastric and gastroesophageal cancer, with initial clinical data expected in the third quarter of 2026. Other ISAC programs targeting CEA and PD‑L1, and the Dectin‑2 agonist BDC‑3042, remain on hold pending proof‑of‑concept for BDC‑4182.